All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
SHANGHAI – Looking to create synergies between its own expertise and growing pool of small and medium biotech ventures in China, Boehringer Ingelheim Pharmaceuticals GmbH (BI) plans to build the first international biopharma contract manufacturing facility (CMO) in the country with mammalian cell technology.